Online Articles: Clinical and Laboratory ObservationsA Novel Use of Romiplostim for SARS-CoV-2–induced ThrombocytopeniaSchneider, Coursen W. MD*; Penney, Scott W. MD†; Helfrich, Alison M. DO‡; Hartman, Kip R. MD†; Lieuw, Kenneth MD, PhD† Author Information Departments of *Pediatrics †Pediatric Hematology/Oncology ‡Pediatric Infectious Disease, Walter Reed National Military Medical Center, Bethesda, MD C.W.S. and S.W.P. contributed equally. The views expressed in this article are those of the authors and do not reflect the official policy of the Department of Army/Navy/Air Force, Department of Defense, or US Government. The authors declare no conflict of interest. Reprints: Kenneth Lieuw, MD, PhD, Department of Pediatric Hematology/Oncology, Walter Reed National Military Medical Center, 4493 North Palmer Road, Bethesda, MD 20889 (e-mail: [email protected]). Journal of Pediatric Hematology/Oncology: August 2021 - Volume 43 - Issue 6 - p e788-e790 doi: 10.1097/MPH.0000000000001961 Buy Metrics Abstract The literature regarding coronavirus disease of 2019 (COVID-19) infection in pediatrics indicates that children have less severe clinical presentations and lower mortality rates. There remains limited data regarding hematologic sequelae in pediatric patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Romiplostim has shown a platelet response in pediatric patients with chronic immune thrombocytopenic purpura, and eltrombopag is proven to increase platelet counts in patients with inherited thrombocytopenia. We review SARS-CoV-2–associated thrombocytopenia and present a pediatric patient with acute on chronic thrombocytopenia in the setting of COVID-19 with subsequent platelet recovery using romiplostim. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.